These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 25163973)

  • 1. Dengue fever: theories of immunopathogenesis and challenges for vaccination.
    Remy MM
    Inflamm Allergy Drug Targets; 2014; 13(4):262-74. PubMed ID: 25163973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New insights into the immunopathology and control of dengue virus infection.
    Screaton G; Mongkolsapaya J; Yacoub S; Roberts C
    Nat Rev Immunol; 2015 Dec; 15(12):745-59. PubMed ID: 26603900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges in Dengue Vaccines Development: Pre-existing Infections and Cross-Reactivity.
    Izmirly AM; Alturki SO; Alturki SO; Connors J; Haddad EK
    Front Immunol; 2020; 11():1055. PubMed ID: 32655548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges for the formulation of a universal vaccine against dengue.
    Chokephaibulkit K; Perng GC
    Exp Biol Med (Maywood); 2013 May; 238(5):566-78. PubMed ID: 23856907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms.
    Rothman AL
    Nat Rev Immunol; 2011 Jul; 11(8):532-43. PubMed ID: 21760609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adaptive immune responses to primary and secondary dengue virus infections.
    St John AL; Rathore APS
    Nat Rev Immunol; 2019 Apr; 19(4):218-230. PubMed ID: 30679808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T cell immunity to dengue virus and implications for vaccine design.
    Rivino L
    Expert Rev Vaccines; 2016; 15(4):443-53. PubMed ID: 26560171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dengue Vaccines: Ongoing Challenges and Current Status in the Advancement of Different Candidates.
    Hassan M; Hassan A; Farooq M; Afzal S; Khan MA; Amin I; Shahid M; Idrees M; Shahid AA
    Crit Rev Eukaryot Gene Expr; 2021; 31(5):7-19. PubMed ID: 34591385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunopathological mechanisms in dengue and dengue hemorrhagic fever.
    Green S; Rothman A
    Curr Opin Infect Dis; 2006 Oct; 19(5):429-36. PubMed ID: 16940865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoimmunity in dengue pathogenesis.
    Wan SW; Lin CF; Yeh TM; Liu CC; Liu HS; Wang S; Ling P; Anderson R; Lei HY; Lin YS
    J Formos Med Assoc; 2013 Jan; 112(1):3-11. PubMed ID: 23332423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD8+ T Cells Can Mediate Short-Term Protection against Heterotypic Dengue Virus Reinfection in Mice.
    Zellweger RM; Tang WW; Eddy WE; King K; Sanchez MC; Shresta S
    J Virol; 2015 Jun; 89(12):6494-505. PubMed ID: 25855749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.
    Tsai WY; Durbin A; Tsai JJ; Hsieh SC; Whitehead S; Wang WK
    J Virol; 2015 Jul; 89(14):7348-62. PubMed ID: 25972550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a novel DNA SynCon tetravalent dengue vaccine that elicits immune responses against four serotypes.
    Ramanathan MP; Kuo YC; Selling BH; Li Q; Sardesai NY; Kim JJ; Weiner DB
    Vaccine; 2009 Oct; 27(46):6444-53. PubMed ID: 19580892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A molecular evaluation of dengue virus pathogenesis and its latest vaccine strategies.
    Faheem M; Raheel U; Riaz MN; Kanwal N; Javed F; us Sahar Sadaf Zaidi N; Qadri I
    Mol Biol Rep; 2011 Aug; 38(6):3731-40. PubMed ID: 21107723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of T cells, cytokines and antibody in dengue fever and dengue haemorrhagic fever.
    Fink J; Gu F; Vasudevan SG
    Rev Med Virol; 2006; 16(4):263-75. PubMed ID: 16791836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current issues in dengue vaccination.
    Thomas SJ; Endy TP
    Curr Opin Infect Dis; 2013 Oct; 26(5):429-34. PubMed ID: 23963259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccines licensed and in clinical trials for the prevention of dengue.
    Torresi J; Ebert G; Pellegrini M
    Hum Vaccin Immunother; 2017 May; 13(5):1059-1072. PubMed ID: 28281864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dengue viruses and promising envelope protein domain III-based vaccines.
    Fahimi H; Mohammadipour M; Haddad Kashani H; Parvini F; Sadeghizadeh M
    Appl Microbiol Biotechnol; 2018 Apr; 102(7):2977-2996. PubMed ID: 29470620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective Protection Induced by a Monovalent DNA Vaccine against Dengue Virus (DV) Serotype 1 and a Bivalent DNA Vaccine against DV1 and DV2 in Mice.
    Zheng X; Chen H; Wang R; Fan D; Feng K; Gao N; An J
    Front Cell Infect Microbiol; 2017; 7():175. PubMed ID: 28553618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune response to dengue virus and prospects for a vaccine.
    Murphy BR; Whitehead SS
    Annu Rev Immunol; 2011; 29():587-619. PubMed ID: 21219187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.